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Summary
Background:  rpoB  gene  mutations  in  Mycobacterium  tuberculosis  (MTB)  make  the
bacteria  resistant  to  rifampicin.  Thus,  these  mutations  are  surrogate  markers  for
multi-drug  resistance  (MDR).  The  objective  of  this  study  was  to  evaluate  an  allele-
speciﬁc  multiplex-polymerase  chain  reaction  (MAS-PCR)  assay  to  detect  mutations
at  codons  516,  526  and  531  of  the  rpoB  gene.
Methods:  In  total,  127  M.  tuberculosis  clinical  isolates  were  subjected  to  standard
drug  susceptibility  tests.  A  MAS-PCR  assay  was  then  performed  to  detect  mutations
in  the  rpoB  gene.  Three  different  allele-speciﬁc  PCR  assays  were  performed  (single-
 ampliﬁed  products  were  sequenced.step  MAS-PCR)  and  the
Results:  Of  the  127  isolates,  69  (54.3%)  were  multidrug  resistant  M.  tuberculosis
(MDR-TB),  21  (16.5%)  were  rifampicin  mono-resistant  and  37  (29.1%)  were  drug  sus-
ceptible.  The  frequency  of  mutations  at  codons  531,  526  and  516  was  54.4%,  18.9%
and  5.6%,  respectively.  A  triple  mutation  was  found  in  4  (4.4%)  isolates.  Mutations
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in  regions  other  than  the  81-bp  region  were  observed  at  codons  413  (11.1%),  511
(12.2%)  and  521  (15.6%)  of  the  rpoB  gene.
Conclusions:  The  simplicity  and  speciﬁcity  of  the  MAS-PCR  assay  allows  for  easy  imple-
boratories  to  detect  rifampicin  drug  resistance  in  MDR-TB
dulaziz  University  for  Health  Sciences.  Published  by  Elsevier
ed.
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Introduction
Worldwide,  there  are  an  estimated  9 million  new
cases and  1.4  million  deaths  caused  by  Mycobac-
terium tuberculosis  (MTB)  infections  [1].  These
numbers  are  increasing  due  to  the  increasing
emergence and  spread  of  multi-drug  resistant  M.
tuberculosis  strains  (MDR-TB).  MDR-TB  strains  are
now a  serious  threat  to  public  health  control  sys-
tems and  do  not  have  effective  treatment  regimens
[2].  Rifampicin  (RIF)  and  isoniazid  (INH)  are  the
drugs of  choice  to  treat  MTB  infections  [3]. How-
ever, organisms  have  started  showing  resistance
to these  drugs.  RIF  resistance  (RIFr)  is  caused  by
mutations  in  a  81-bp  region  (codons  507—533,  27
amino acids)  of  the  rpoB  gene  [4]. Therefore,
this 81-bp  region  is  called  the  rifampicin  resis-
tance determining  region  (RRDR)  (RNA  polymerase
enzyme binding  site)  [3—6]. It is  imperative  to  iden-
tify rifampicin  resistant  strains  and  prevent  the
spread  of  MDR-TB  [6,7].  Cost-effective,  sensitive
PCR-based  techniques  followed  by  DNA-sequencing
of targeted  individual  codons  are  used  to  deter-
mine RIF  resistance  [8,9]. One  such  PCR  technique
is multiplex  allele-speciﬁc  PCR  (MAS-PCR),  which
detects  RIFr.  MAS-PCR  utilizes  three  different  spe-
ciﬁc primers  to  detect  mutations  at  codons  516,  526
and 531.  These  mutations  are  responsible  for  drug
resistance  in  the  majority  of  RIF  resistant-strains
(70 to  95%)  [10—12].
Therefore,  this  study  aimed  to  evaluate  a  rapid
detection  method  of  common  mutations  in  the
RRDR in  the  rpoB  gene  of  RIFr MTB  clinical  isolates
using a  MAS-PCR  assay  followed  by  DNA  sequencing.
Materials and methods
Study settings
In total,  127  samples  were  received  from
TB-suspected  patients  (both  in-patient  and
out-patient)  between  January  2011  and  July  2013.
Samples  were  collected  from  out-patients  based
on clinical  symptoms,  smear  results  and  chest
M
M
p
5-ray  analyses  that  were  positive  for  TB  and
rom hospitalized  patients  based  on  a  physician’s
ecommendation.
acterial strains and drug susceptibility
esting
pecies  identiﬁcation  was  performed  using  conven-
ional mycobacteriological  methods,  such  as  colony
orphology  in  Lowenstein—Jensen  (LJ)  medium,
cid-fast staining  (AFB),  and  biochemical  tests
13]. Sputum  samples  were  processed  and  used  for
noculation on  LJ  slants  and  DNA  isolation.  Tests
ere performed  to  differentiate  the  MTB  complex
rom non-tuberculous  mycobacteria  (NTM)  in  clini-
al specimens.
A drug  susceptibility  test  (DST)  was  performed
ith 40  g/mL  of  rifampicin  to  identify  RIFr [14].
. tuberculosis  H37Rv  (ATCC  27294),  standard  lab-
ratory drug  susceptible  and  MDR-TB  strains  were
sed as  controls.
xtraction of mycobacterial DNA
TB  clinical  isolates  were  subjected  to  genomic
NA extraction  following  a phenol:  chloroform
xtraction method  [15].  Isolated  genomic  DNA  was
efrigerated  at 4 ◦C  for  further  use.
CR procedures
mpliﬁcation  of  IS6110  (123-bp)  using  primers  IS1
nd IS2  for  species  level  mycobacterium  iden-
iﬁcation (Table  1) was  performed  as  described
reviously [1]. Ampliﬁcation  of  the  rpoB  gene  in
oth RIFs and  RIFr isolates  was  performed  with  the
rimers  rpoB95  and  rpoB397  [16]  (Table  1),  whichultiplex  allele-speciﬁc  PCR  (MAS-PCR)
AS-PCR  was  performed  using  three  allele-speciﬁc
rimers targeting  mutated  codons  516,  526,  and
31 of  the  rpoB  gene  as  previously  described  [11].
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Table  1  MAS-PCR  Primers  and  DNA  sequencing  primers  to  detect  RIF  resistance  mutations  of  M.  tuberculosis
clinical  isolates.
Target  gene  Primer/alleles  Primer  sequences  (5′—3′)  PCR  product  length  (bp)
IS6110a IS1  GTGAGGGCATCGAGGTGG 123
IS2  CGTAGGCGTCGGTCACAAA
rpoB
rpoB  516  (+)  CAGCTGAGCCAATTCATGGA 218
RIRm  (−) TTGACCCGCGCGTACAC
rpoB  526  (+) CTGTCGGGGTTGACCCA 185
RIRm  (−) TTGACCCGCGCGTACAC
rpoB  531  (+) CACAAGCGCCGACTGTC 170
RIRm  (−)  TTGACCCGCGCGTACAC
rpoB
RRDRb
rpoB  95  CCACCCAGGACGTGGAGGCGATCACAC 329
rpoB  397  CGTTTCGATGAACCCGAACGGGTTGAC
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Da For species identiﬁcation and routine TB diagnosis.
b The ampliﬁed product containing RRDR region of rpoB gen
he  complete  list  of  primers  used  in  this  study
s listed  in  Table  1. The  MAS-PCR  primers  bind
peciﬁcally to  wild-type  sequences  of  the  rpoB
ene (codons  516,  526,  and  531).  If  a  mutated
llele is  present,  there  will  not  be  an  ampliﬁcation,
hich results  in  the  absence  of  the  corresponding
and on  an  agarose  gel  [11].
NA sequencing analysis
he  PCR-ampliﬁed  fragment  (329-bp)  of  the  rpoB
ene containing  RRDR  (81-bp)  was  subjected  to
irect DNA  sequencing  (Indian  Institute  of  Technol-
gy (IIT),  Chennai,  India)  to  conﬁrm  the  results  from
he MAS-PCR  assay  and  identify  mutations  at  spe-
iﬁc bases  in  codons  516,  526  and  531  of  the  rpoB
ene and  other  regions.
tatistical analysis
he  sensitivity  and  speciﬁcity  of  the  MAS-PCR  assay
as calculated  based  on  the  detection  of  RIFr in
linical  isolates  using  a  DNA  sequencing  method  as
he gold  standard  and  a  conventional  drug  suscep-
ibility  test  as  a  control.  MedCalc  (version  12.5)
MedCalc  Software,  Ostend,  Belgium)  was  used  to
alculate and  interpret  the  test  parameters  for  sen-
itivity and  speciﬁcity  [17].
esults
onventional assaysolony  morphology,  biochemical  tests  and  PCR
mpliﬁcation  of  IS6110  were  performed  on  all  of  the
solates from  conﬁrmed  MTB  infections  (other  rou-
ine investigations  are  not  illustrated  in  this  paper).
T
r
p
u DNA sequencing.
rug susceptibility testing
f  the  127  M.  tuberculosis  clinical  isolates,  69
54.3%)  were  MDR-TB,  21  (16.5%)  were  RIF  mono
esistant  and  37  (29.1%)  were  drug  susceptible
gainst speciﬁc  anti-TB  drugs.
AS-PCR assay
AS-PCR  was  performed.  After  ampliﬁcation,  the
CR products  were  subjected  to  agarose  gel  elec-
rophoresis  (Fig.  1). The  RIFr phenotype  is  classiﬁed
y the  absence  of  (one  or  more)  the  correspond-
ng bands  in  the  isolates:  218-bp  (Fig.  1a),  185-bp
Fig.  1b),  and  170-bp  (Fig.  1c).  RIFs isolates  showed
ands in  the  gel.  A  concordant  result  was  obtained
y DNA  sequencing  the  RRDR  of  all  of  the  isolates
ncluded in  this  study.  Isolates  susceptible  to  RIF
roduced  ampliﬁed  products.  Isolates  resistant  to
IF failed  to  produce  ampliﬁed  products.  The  most
requent  mutation  was  observed  at  codon  531  of  the
poB gene  in  68  (75.5%)  strains,  followed  by  a muta-
ion at  codon  526  in  17  (18.9%)  strains  and  a  muta-
ion at  codon  516  in  5  (5.6%)  strains.  A  mutation
t codon  531  was  combined  with  526  codon  muta-
ions in  15  strains  (16.7%),  and  only  4  isolates  (4.4%)
howed triple  mutation  at  codons  516,  526  and  531
Table  2).  All  of  the  susceptible  isolates  contained
ild-type  sequences.  The  results  of  the  in  vitro
onventional drug  susceptibility  tests  revealed  sus-
eptible patterns  for  the  susceptible  isolates.
NA sequencinghe  conventional  solid  DST  and  MAS-PCR  assay
esults were  further  compared  with  the  ampliﬁed
roducts of  the  rpoB  gene  (329  bp)  containing  RRDR
sing automated  DNA  sequencing.  The  frequencies
622  R.  Thirumurugan  et  al.
Figure  1  Examples  of  banding  proﬁles  generated  by  MAS-PCR  with  puriﬁed  DNA  preparations  from  M.  tuberculosis
clinical  isolates  by  targeting  rpoB  codons:  codon  531  (1a),  codon  526  (1b),  and  codon  516  (1c).  In  general,  the  presence
of  the  bands  corresponded  to  size:  codon  516  at  218  bp,  codon  526  at  185  bp  and  codon  531  at  170  bp  represent  the
presence  of  the  wild  type  allele  and  RIF  susceptible  strains.  The  absence  of  these  bands  indicates  the  mutated  alleles
of  RIF  resistance  strains.  (a)  Lanes  1,  15  and  16:  100-bp  DNA  Ladder  (HiMedia,  India),  Lane:  2,  positive  control  M.
tuberculosis  H37Rv  strain;  Lanes:  3—14  and  17—27,  218-bp  product  of  strains  with  rpoB  516  mutant  alleles  (GTC,  TAC,
and  GGC).  (b)  Lanes  1,  14:  100-bp  DNA  Ladder  (HiMedia,  India),  Lane:  2,  Positive  control  M.  tuberculosis  H37Rv;  Lanes
3—13  and  15—26,  185-bp  product  of  strains  with  rpoB  526  mutant  alleles  (GAC,  TAC,  and  CTC).  (c)  Lanes  1,  10  and  24:
trol
CG  
i
5
o
D
S
s100-bp  DNA  Ladder  (HiMedia,  India),  Lane:  2,  Positive  con
170-bp  product  of  strains  with  rpoB  531  mutant  alleles  (T
of  the  mutations  identiﬁed  in  the  127  isolates
are shown  in  Tables  2 and  3. Mutations  in  regions
other than  the  RRDR  were  observed  and  widely
distributed among  the  RIFr strains.  They  were  also
observed  in  the  drug-resistant  phenotypes  using  in
vitro DST.
In total,  three  strains  (3.3%)  of  MDR-TB  failed
to amplify  using  the  MAS-PCR  assay,  but  their
sequences were  determined  by  DNA  sequencing.  In
total, mutations  in  regions  other  than  the  81-bp
region of  the  rpoB  gene  were  observed  in  73  (57.5%)
O
l
i
Table  2  Common  mutations  in  RRDR  region  detected  by  M
frequency.
Gene  Rifampicin
rpoB
Mutations  D516V  H526Y  S531L
No.  of  strains  5  17  49  
Frequency  (%)  5.6  18.9  54.4   M.  tuberculosis  H37Rv;  Lanes  3—9,  11  to  23  and  25—27,
and  TTG).
solates  (Table  3). Mutations  at  codons  413  (11.1%),
11 (12.2%)  and  521  (15.6%)  were  frequently
bserved. The  mutations  detected  by  MAS-PCR  and
NA sequencing  are  listed  in  Tables  2  and  3.
tatistical analysis: sensitivity and
peciﬁcityf  the  total  127  isolates,  68  of  the  69  MDR-TB  iso-
ates,  19  of  the  21  RIFr (rifampicin  mono  resistant)
solates and  36  of  the  37  susceptible  isolates  were
AS-PCR  assay  associated  with  RIF-resistance  and  their
 H526Y  +  S531L  D516V  +  H526Y  +  S531L
15  4
16.7  4.4
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Table  3  Frequency  of  other  mutations  found  in  rpoB  gene  among  RIF  resistant  M.  tuberculosis  isolates.
Codon  no  Nucleotide  changes  Amino  acid  changes  No.  of  strains  (%)
413  AAC  →  CAC  Asn  →  His  10  (11.1)
435  GAC  →  GAG  Asp  →  Glu  6  (6.7)
451  GCA  →  GAC Ala →  Asp 8 (8.9)
511  CGC  →  TGC Arg  →  Cys 11  (12.2)
513  GTC  →  GAC  Val  →  Asp  9  (10)
521  GAG  →  GAC  Glu  →  Asp  14  (15.6)
451  + 511  GCA  →  GAC,  CGC  →  TGC  Ala  →  Asp,  Arg  →  Cys  7  (7.8)
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s513  + 521  GTC  →  GAC,  GAG  →  GAC  
uccessfully  identiﬁed  using  the  MAS-PCR  assay.  The
ensitivity of  MAS-PCR  to  detect  drug  resistance  in
linical isolates  (both  MDR-TB  and  RIFr isolates)  was
6.7%, and  the  speciﬁcity  was  97.3%.
iscussion
arly  detection  of  drug  resistance  in  MTB  allows  for
 timely  implementation  of  a  treatment  regimen
hat can  better  control  the  infection  [1,12,18,19].
uring the  last  few  decades,  several  approaches
ave been  proposed  for  the  rapid  detection  of
DR-TB in  a  clinical  setting,  including  both  geno-
ypic and  phenotypic  methods  [11,12,15,16,19,20].
n almost  all  cases,  molecular  methods  are  the
efault for  detecting  RIF  drug  resistance  because
t is  considered  to  be  a  surrogate  marker  for  MDR-
B [15,16,19,20].  The  advantage  of  a  genotypic
ethod is  that  it  requires  a  shorter  time  than  other
outine  methods.  However,  not  all  of  the  molecular
ethods for  detecting  drug  resistance  are  low-cost.
herefore,  they  are  not  routinely  implemented  in
ll clinical  mycobacteriology  laboratories  [4,21].
Prior to  the  validation  and  optimization  of  MAS-
CR, routine  molecular  diagnostic  assays,  such  as
he IS6110  and  mtp40  PCR  assays,  were  performed
n DNA  samples  of  MTB  clinical  isolates:  (i)  IS6110-
CR, a  routine  diagnosis  of  TB  infection  [1], and  (ii)
tp40-PCR,  for  species  identiﬁcation  of  MTB  from
TM isolates  [1].  Consequently,  MAS-PCR  analysis
as performed  on  puriﬁed  genomic  DNA  samples
rom 90  RIFr isolates  and  37  RIFs isolates  from
atients enrolled  from  2011  to  2013.
The  MAS-PCR  assay  generated  banding  proﬁles
or different  mutations  in  the  rpoB  gene  (codons
16, 526,  and  531)  that  were  successfully  identi-
ed by  the  respective  codon-speciﬁc  primer  PCR
Fig.  1).  The  stringency  of  allele-speciﬁc  PCR  has
een standardized.  PCR  assays  targeting  speciﬁc
oint  mutations  were  performed  in  duplicate  or
riplicate.  Therefore,  MAS-PCR  successfully  identi-
ed the  rpoB516,  rpoB526  and  rpoB531  mutations
o
b
o
TVal  →  Asp,  Glu  →  Asp  8  (8.9)
n  clinical  isolates.  The  most  prevalent  mutations
ffected  codon  531  (75.5%),  followed  by  codon
26 (18.9%)  and  codon  516  (5.6%).  Among  the
rug resistant  isolates,  mutations  at  codon  531
ccurred  alone  in 49  (54.4%)  cases.  A  combination
f mutations  was  also  observed  as  a double  muta-
ion associating  codons  526  and  531  in  15  (16.7%)
trains and  a  triple  mutation  at  codons  516,  526  and
31 in  4  (4.4%)  strains.  Several  supporting  studies
howed  that  the  occurrence  of  a  frequent  muta-
ion at S531L  is  the  most  predominant  worldwide
3,11,12,15,16,19,20,22—24].
The  rpoB  329-bp  ampliﬁed  product  of  all  of  the
IFs and  RIFr isolates  in  the  RRDR  was  sequenced.
he mutations  in  the  RRDR  were  identiﬁed,  and  the
esults were  analyzed  in  parallel  with  the  MAS-PCR
nd conventional  drug  susceptibility  results.  The
onventional  solid  LJ  system  exhibited  the  same
esult patterns.  The  extent  of  drug  resistance  was
lso analyzed.  Of  the  90  RIFr isolates,  7  demon-
trated a level  of resistance  against  RIF  at  a high  MIC
>128 mg/L).  However,  other  RIFr isolates  showed
esistance  at  40  g/ml.  There  was  no  correlation
etween the  presence  of  a  particular  codon  muta-
ion and  the  level  of  drug  resistance  in  the  clinical
solates.  Almost  all  of  the  isolates  had  a  531  codon
utation.
The conventional  assay  failed  to  detect  a  drug
esistance phonotype  in  5  (3.9%)  strains  due  to  a
ow bacilli  load.  Genomic  DNA  was  used  to  acquire
 resistance  pattern  using  molecular  methods.  The
AS-PCR method  failed  to  identify  drug  resistance
n two  strains  (2.2%).  In  this  study  unique  mutations
n the  RRDR  at  codons  511  and  521  were  frequently
ound in  11  (12.2%)  and  14  (15.6%)  isolates,  respec-
ively (Table  3).  Of  the  21  RIFr isolates,  2  (9.5%)
howed no  bands  from  the  MAS-PCR  assay  because
f the  presence  of  other  codon  mutations.  Several
tudies were  performed  worldwide  and  reported
ccurrences of  other  mutations  in  and  out  of  the  81-
p RRDR  [19,20,23—25].  The  presence  of  mutations
utside the  81-bp  region  have  rarely  been  reported.
hey were  reported  in  less  than  5%  of  RIFr strains  in
624  
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NA  sequencing  studies  [3,20].  The  positive  predic-
ive value  of  MAS-PCR  was  98.9%,  and  the  negative
redictive value  was  92.3%  (Table  4).  Although,  a
equencing method  is  a costly  and  laborious  process
o conﬁrm  results,  it  can  be  incorporated  to  diag-
ose  drug  resistant  isolates  with  high  speciﬁcity  and
fﬁciency. Thus,  it  is  needed  to  detect  drug  resis-
ance in  isolates  due  to  rare,  clinically  important
utations.
onclusions
n  conclusion,  MAS-PCR  was  performed  to  detect
ommon mutations  of  the  rpoB  gene.  It  is  a  sim-
le and  rapid  molecular  method  to  identify  RIF
rug resistance  in  M.  tuberculosis  clinical  isolates.
ore importantly,  the  interpretation  of  the  MAS-
CR results  is  easier  than  other  methods.  It  is
nexpensive and  requires  fewer  resources  to  set  up.
t can  also  be  implemented  with  routine  clinical
esources in  laboratories  in  resource-poor  settings.
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